J&J’s Rybrevant linked to longest median OS in exon 20 EGFR NSCLC
RegulatoryapprovedRybrevantPositive
AI Analysis
Summary
J&J's Rybrevant was approved for NSCLC with EGFR exon 20 insertion mutations after meeting its primary endpoint of progression-free survival, and demonstrated the longest median overall survival in this indication.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Approved in NSCLC with EGFR exon 20 insertion mutations; trial met primary endpoint of PFS
Importance:8/10
Sentiment:
0.80
NSCLCEGFR exon 20PFSOSapproval
Related Companies
Read the original article
Published by Clinical Trials Arena on September 14, 2026 10:41 AM